Abstract:Background As one of the common subtypes of non-small lung cancer, lung squamous cell carcinoma (LUSC) patients with advanced stage have few choices of treatment strategies. Therefore, it is urgent to discover genes that are associated with the survival and efficacy of immunotherapies. Method Differential gene expression analyses were conducted using TCGA LUSC bulk-sequencing and single-cell RNA-sequencing data. Prognostic genes were identified from the TCGA LUSC cohort. Protein expression validation and survival analyses were performed. Experiments were conducted to explore the underlying mechanisms. In addition, the correlation between gene expression and pathological response to adjuvant immunochemotherapy was also investigated. Results After a series of bioinformatic analyses, solute carrier family 2 member 1(SLC2A1), encoding glucose transporter-1 (GLUT1), was found to be differentially expressed between tumor and normal tissues. GLUT1 was subsequently identified as an independent prognostic factor for LUSC. GSEA analysis revealed the glycolysis metabolism pathway of KEGG enriched in SLC2A1 high tumor tissues. LASSO analyses revealed that tumor tissues with high expression of SLC2A1 were associated with high levels of protein lactylation. We found that SLC2A1 was preferentially expressed by SPP1 + macrophages in the tumor microenvironment, and the expression of SLC2A1 was associated with the abundance of SPP1 + macrophages. Immunofluorescence demonstrated GLUT1 and HIF1α colocalization in tumor-infiltrating macrophages. In vitro experiments showed HIF-1α-induced macrophage polarization under hypoxia, and GLUT1 inhibition blocked this polarization. In addition, SLC2A1 was negatively associated with the common immune checkpoint molecules, such as programmed cell death 1(PD-1), T cell immunoreceptor with Ig and ITIM domains (TIGIT), cytotoxic T-lymphocyte associated protein 4 (CTLA4) and lymphocyte activating 3 (LAG3), while showed a positive association with CD44. Finally, we observed that there was a significant correlation between pre-adjuvant-treatment GLUT1 expression and the pathological response. Conclusion SLC2A1 expression was differentially upregulated in tumor tissues, and elevated GLUT1 expression was associated with worse survival and poor pathological response to adjuvant immunochemotherapy. Upregulation of GLUT1 promoted macrophage polarization into the M2 phenotype. The findings will contribute to guiding the treatment selection for LUSC patients and providing personalized immunotherapy strategies.

SLC11A1 As a Stratification Indicator for Immunotherapy or Chemotherapy in Patients with Glioma

SLC39A1 contribute to malignant progression and have clinical prognostic impact in gliomas

Identification of SLC2A1 as a predictive biomarker for survival and response to immunotherapy in lung squamous cell carcinoma

Elevated SLC3A2 associated with poor prognosis and enhanced malignancy in gliomas

Cell Death-Related Biomarker SLC2A1 Has a Significant Role in Prognosis Prediction and Immunotherapy Efficacy Evaluation in Pan-Cancer

Overexpression of Cell-Surface Marker SLC16A1 Shortened Survival in Human High-Grade Gliomas

Influence of SLC40A1 on Cytokine Interactions and Immune Infiltration in Glioblastoma

SLC11A1 associated with tumor microenvironment is a potential biomarker of prognosis and immunotherapy efficacy for colorectal cancer

Prognosis and therapeutic significance of IGF-1R-related signaling pathway gene signature in glioma

Cuproptosis-related gene SLC31A1 expression correlates with the prognosis and tumor immune microenvironment in glioma

Prognostic value of lactate transporter SLC16A1 and SLC16A3 as oncoimmunological biomarkers associating tumor metabolism and immune evasion in glioma

Identification of the novel prognostic biomarker, MLLT11, reveals its relationship with immune checkpoint markers in glioma

Serine and Glycine Metabolism-Related Gene Expression Signature Stratifies Immune Profiles of Brain Gliomas, and Predicts Prognosis and Responses to Immunotherapy.

SLC2A1 Plays a Significant Prognostic Role in Lung Adenocarcinoma and is Associated with Tumor Immunity Based on Bioinformatics Analysis.

Exploring the multifaceted role of key lncRNA in glioma: From genetic expression to clinical implications and immunotherapy potential

Integrated machine learning screened glutamine metabolism-associated biomarker SLC1A5 to predict immunotherapy response in hepatocellular carcinoma

S100A gene family: immune-related prognostic biomarkers and therapeutic targets for low-grade glioma

CSF3R as a potential prognostic biomarker and immunotherapy target in glioma

A Novel Immune-Related Prognostic Biomarker and Target Associated With Malignant Progression of Glioma

The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma